Thomas Hennessey
Director/Board Member chez AutoGenomics, Inc.
Profil
Thomas V. Hennessey est membre du conseil d'administration d'AutoGenomics, Inc. Dans le passé, il a été directeur de l'exploitation et des finances d'AutoImmune, directeur de l'exploitation et des finances de Boston Scientific Corp, directeur de l'exploitation et des finances de Cambridge Heart, directeur des finances de LumeRx, directeur de l'exploitation et des finances de Photovac, directeur de l'exploitation et des finances de Behring Diagnostics Business, directeur de l'exploitation et des finances de PHT Corp, directeur de l'exploitation et des finances de Medical Diagnostics, Inc. et directeur de l'exploitation et des finances de SonaMed Corp. Thomas V. Hennessey est titulaire d'un diplôme d'études supérieures et d'un diplôme de premier cycle du Massachusetts Institute of Technology et d'un MBA de la Harvard Business School.
Postes actifs de Thomas Hennessey
| Sociétés | Poste | Début |
|---|---|---|
AutoGenomics, Inc.
 AutoGenomics, Inc. Medical SpecialtiesHealth Technology AutoGenomics, Inc. engages in the design, development, manufacture, and marketing of an automated, microarray-based multiplexing diagnostic platform. The company was founded by Fareed Kureshy, Shailendra Singh, and Ramanath Vairavan in April 1999 and is headquartered in Carlsbad, CA. | Director/Board Member | 01/01/2008 |
Hopewell Therapeutics, Inc.
 Hopewell Therapeutics, Inc. BiotechnologyHealth Technology Hopewell Therapeutics, Inc. is a company that is focused on discovering, synthesizing, and developing tissue-targeted lipid nanoparticles (TTLNPs) to bring genomic medicines to patients. The company is based in Woburn, MA and was founded in 2018 by Qiaobing Xu. Hopewell is pursuing opportunities to redefine the non-viral delivery space for novel genomic medicines by designing systemically administered LNPs to specifically target extrahepatic tissues and cells throughout the body. The company has built a robust intellectual property portfolio with an expansive library of ionizable lipids and has established partnerships with several industry-leading companies. Hopewell is developing its own internal pipeline, initially targeting diseases of the lung, while concurrently exploring the potential of its TTLNP platform for patients with unmet needs in oncology, infectious diseases, rare genetic diseases, and neurological disorders. Louis Brenner has been the CEO of the company since 2022. | Director/Board Member | - |
Anciens postes connus de Thomas Hennessey
| Sociétés | Poste | Fin |
|---|---|---|
Photovac, Inc.
 Photovac, Inc. Medical SpecialtiesHealth Technology Part of Applied Biosystems, Inc., Photovac, Inc. is a Canadian company that specializes in portable environmental instruments. The private company is based in Markham, Canada. Photovac was acquired by Applera Corp. on April 13, 1995. | Director of Finance/CFO | 01/01/2003 |
PHT Corp.
 PHT Corp. Packaged SoftwareTechnology Services PHT Corp. designs and develops software applications. The firm offers biopharmaceutical clients comprehensive services for acquiring, managing, and analyzing data collected directly from patients through all phases of clinical development. Its electronic clinical outcome assessment (eCOA) system collects and reports secure real-time patient data from smartphones, tablets, and the web. The company was founded by Stephen Raymond in 1994 and is headquartered in Boston, MA. | Director of Finance/CFO | - |
SonaMed Corp.
 SonaMed Corp. Medical SpecialtiesHealth Technology SonaMed Corp. designs, develops, manufactures and markets automated, internet ready screening and monitoring systems for the hospital, physician's office and home monitoring markets. The company was founded by William Ford Dolphin in 1994 and is headquartered in Waltham, MA. | Director of Finance/CFO | - |
| CAMBRIDGE HEART, INC. | Director of Finance/CFO | - |
| BOSTON SCIENTIFIC CORPORATION | Director of Finance/CFO | - |
Formation de Thomas Hennessey
| Massachusetts Institute of Technology | Graduate Degree |
| Harvard Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BOSTON SCIENTIFIC CORPORATION | Distribution Services |
| Entreprise privées | 10 |
|---|---|
AutoImmune, Inc.
 AutoImmune, Inc. Pharmaceuticals: MajorHealth Technology AutoImmune, Inc. develop products to treat autoimmune and other cell-mediated inflammatory conditions. Its products are based on a biological mechanism known as oral tolerance, which provides tissue specific immunosuppression without toxicity or significant side effects. The company was founded in September 1988 and is headquartered in Pasadena, CA. | Health Technology |
Cambridge Heart, Inc.
 Cambridge Heart, Inc. Medical SpecialtiesHealth Technology Cambridge Heart, Inc. engages in the development and commercialization of products for the non-invasive diagnosis of cardiac disease. The company was founded by Jeffrey M. Arnold and Jordan S. Davis on January 16, 1990 and is headquartered in Tewksbury, MA. | Health Technology |
LumeRx, Inc.
 LumeRx, Inc. Medical SpecialtiesHealth Technology LumeRx, Inc. develops radiation technology that eliminates bacteria. It provides minimally invasive and light-based devices for the treatment of peptic ulcer disease. The company was founded by Robert A. Ganz and is headquartered in Newton, MA. | Health Technology |
AutoGenomics, Inc.
AutoGenomics, Inc. Medical SpecialtiesHealth Technology AutoGenomics, Inc. engages in the design, development, manufacture, and marketing of an automated, microarray-based multiplexing diagnostic platform. The company was founded by Fareed Kureshy, Shailendra Singh, and Ramanath Vairavan in April 1999 and is headquartered in Carlsbad, CA. | Health Technology |
| Medical Diagnostics, Inc. | Health Services |
PHT Corp.
PHT Corp. Packaged SoftwareTechnology Services PHT Corp. designs and develops software applications. The firm offers biopharmaceutical clients comprehensive services for acquiring, managing, and analyzing data collected directly from patients through all phases of clinical development. Its electronic clinical outcome assessment (eCOA) system collects and reports secure real-time patient data from smartphones, tablets, and the web. The company was founded by Stephen Raymond in 1994 and is headquartered in Boston, MA. | Technology Services |
Behring Diagnostics Business
 Behring Diagnostics Business Medical SpecialtiesHealth Technology Part of Siemens AG, Behring Diagnostics Business provides diagnostic services. | Health Technology |
Photovac, Inc.
Photovac, Inc. Medical SpecialtiesHealth Technology Part of Applied Biosystems, Inc., Photovac, Inc. is a Canadian company that specializes in portable environmental instruments. The private company is based in Markham, Canada. Photovac was acquired by Applera Corp. on April 13, 1995. | Health Technology |
SonaMed Corp.
SonaMed Corp. Medical SpecialtiesHealth Technology SonaMed Corp. designs, develops, manufactures and markets automated, internet ready screening and monitoring systems for the hospital, physician's office and home monitoring markets. The company was founded by William Ford Dolphin in 1994 and is headquartered in Waltham, MA. | Health Technology |
Hopewell Therapeutics, Inc.
Hopewell Therapeutics, Inc. BiotechnologyHealth Technology Hopewell Therapeutics, Inc. is a company that is focused on discovering, synthesizing, and developing tissue-targeted lipid nanoparticles (TTLNPs) to bring genomic medicines to patients. The company is based in Woburn, MA and was founded in 2018 by Qiaobing Xu. Hopewell is pursuing opportunities to redefine the non-viral delivery space for novel genomic medicines by designing systemically administered LNPs to specifically target extrahepatic tissues and cells throughout the body. The company has built a robust intellectual property portfolio with an expansive library of ionizable lipids and has established partnerships with several industry-leading companies. Hopewell is developing its own internal pipeline, initially targeting diseases of the lung, while concurrently exploring the potential of its TTLNP platform for patients with unmet needs in oncology, infectious diseases, rare genetic diseases, and neurological disorders. Louis Brenner has been the CEO of the company since 2022. | Health Technology |
